Founded at the Abramson Cancer Center at the University of Pennsylvania

Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis

Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis

Journal of Crohn’s and Colitis | 2020

Frank I. Scott; Michelle Luo; Yash Shah; Karen Lasch; Ravy K. Vajravelu; Ronac Mamtani; Blair Fennimore; Mark E. Gerich; James D. Lewis